A recent study led by researchers at the University of Cambridge has uncovered a potential mechanism by which aspirin may help prevent the spread of certain cancers. The study, published in Nature, found that aspirin reduces levels of thromboxane A2 (TXA₂), a molecule produced by platelets that can suppress T-cell activity. By lowering TXA₂, aspirin appears to enhance the immune system’s ability to recognize and attack metastatic cancer cells, particularly in early-stage cancers. This discovery suggests that aspirin could serve as a cost-effective, accessible adjunct to existing cancer treatments, especially in resource-limited settings .
In addition to aspirin, another common painkiller, ketorolac, has shown promise in preventing cancer metastasis. A study from Emory University demonstrated that administering ketorolac before surgery activated the body’s immune response, reducing the likelihood of cancer cells spreading. When combined with low doses of aspirin and omega-3 fatty acids, survival rates in mice improved further. These findings indicate that repurposing existing medications could offer new strategies for cancer prevention and treatment, though further clinical trials are necessary to confirm their efficacy and safety in humans . Click for More Details
